FIG 2.

Comparison of 5′ nuclease genotyping results with those of 23S rRNA sequencing. All 101 samples identified with the 5′ nuclease genotyping assay as wild type were verified by sequencing. All 132 samples, which by the 5′ nuclease genotyping assay were classified as containing M. genitalium with A2058G or A2059G mutations, were verified by sequencing. Four samples that clustered separately from the wild-type and A2058G/A2059G samples yielded either A2058C/T mutations or contained a mixture of wild-type and A2058G alleles when sequenced. Six of the 259 samples were not evaluated because the samples were not successfully genotyped by sequencing or by the 5′ nuclease genotyping assay. The figure samples that by sequencing contain mutations associated with macrolide resistance are indicated with red-shaded boxes. Samples without mutations, i.e., categorized by sequencing as macrolide susceptible, are indicated by green-shaded boxes. Of the 253 samples genotyped by sequencing, 109 (43.1%) were wild type, 75 (29.6%) contained the A2058G mutation, 65 (25.7%) contained the A2059G mutation, 2 (0.8%) contained the A2058T mutation, and 1 (0.4%) contained an A2058C mutation. The remaining sample displayed a mixed sequence chromatogram containing wild-type and A2058G results. In all, 144 of the 253 sequenced samples contained mutations conferring resistance to macrolides (56.9%).